SEC Form 4

FORM 4		UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940	OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5
	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* ORONSKY ARNOLD L (Last) (First) (Middle) C/O PMV PHARMACEUTICALS, INC. 8 CLARKE DRIVE, SUITE 3 (Street) CRANBURY NJ 08512 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol PMV Pharmaceuticals, Inc. [ PMVP ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director X 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 09/25/2020
	4. If Amendment, Date of Original Filed (Month/Day/Year) 09/29/2020	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/25/2020		P		55,555	A	$18	55,555	I	See footnote(1)
Common Stock	09/29/2020		C		1,620,101	A	(2)	1,675,656	I	See footnote(1)
Common Stock	09/29/2020		C		3,488,398	A	(2)	5,164,054	I	See footnote(1)
Common Stock	09/29/2020		C		1,040,654	A	(2)	6,204,708	I	See footnote(1)
Common Stock	09/29/2020		C		265,203	A	(2)	6,469,911	I	See footnote(1)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series Seed Preferred Stock	(2)	09/29/2020		C			1,620,101	(2)	(2)	Common Stock	1,620,101	$0.00	0	I	See footnote(1)
Series A Preferred Stock	(2)	09/29/2020		C			3,488,398	(2)	(2)	Common Stock	3,488,398	$0.00	0	I	See footnote(1)
Series B Preferred Stock	(2)	09/29/2020		C			1,040,654	(2)	(2)	Common Stock	1,040,654	$0.00	0	I	See footnote(1)
Series C Preferred Stock	(2)	09/29/2020		C			265,203	(2)	(2)	Common Stock	265,203	$0.00	0	I	See footnote(1)

Explanation of Responses:

1. The shares are directly held by InterWest Partners X, LP ("InterWest X"). InterWest Management Partners X, LLC ("IMP X"), as the general partner of InterWest X, may be deemed to beneficially own the shares held by InterWest X. The Reporting Person is a managing director of IMP X, and as such may be deemed to beneficially own the shares held by InterWest X. The Reporting Person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein.

2. The shares of each of the Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date.

Remarks:

This Form 4/A has been filed to correct an error in the number of shares reported as purchased by IW10 on September 25, 2020.

	/s/ Karen Wilson, Attorney-in-Fact for Arnold L. Oronsky	10/02/2020
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.